" Defence Therapeutics (CSE:DTC) begins IND-enabling testing of Its AccuTOX lead compound against breast cancer

Defence Therapeutics (DTC) has begun its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited.

" Defence Therapeutics (CSE:DTC) Accum boosts delivery effectiveness of the CRISPR/Cas9 protein

Defence Therapeutics (DTC) has announced that its Accum platform can potently enhance Cas9 delivery in target cells, positively impacting the CRISPR industry.

" Defence Therapeutics (CSE:DTC) announces agreement with the Lady Davis Institute

Defence Therapeutics (DTC) has announced an agreement with the Lady Davis Institute cell processing center (CPC) at the Jewish General Hospital in Montreal.